These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18683917)

  • 1. The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
    Zhao C; Sun M; Bennani YL; Gopalakrishnan SM; Witte DG; Miller TR; Krueger KM; Browman KE; Thiffault C; Wetter J; Marsh KC; Hancock AA; Esbenshade TA; Cowart MD
    J Med Chem; 2008 Sep; 51(17):5423-30. PubMed ID: 18683917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel H3 receptor antagonists with improved pharmacokinetic profiles.
    Santora VJ; Covel JA; Hayashi R; Hofilena BJ; Ibarra JB; Pulley MD; Weinhouse MI; Semple G; Ren A; Pereira G; Edwards JE; Suarez M; Frazer J; Thomsen W; Hauser E; Lorea J; Grottick AJ
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4133-6. PubMed ID: 18554904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
    Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
    Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist.
    Esbenshade TA; Fox GB; Krueger KM; Baranowski JL; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan JB; Faghih R; Bennani YL; Williams M; Hancock AA
    Biochem Pharmacol; 2004 Sep; 68(5):933-45. PubMed ID: 15294456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
    Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
    J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties.
    Esbenshade TA; Fox GB; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Pan L; Wetter J; Marsh K; Bennani YL; Cowart MD; Sullivan JP; Hancock AA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):165-75. PubMed ID: 15608078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel heterocyclic-substituted benzofuran histamine H3 receptor antagonists: in vitro properties, drug-likeness, and behavioral activity.
    Cowart M; Gfesser GA; Browman KE; Faghih R; Miller TR; Milicic I; Baranowski JL; Krueger KM; Witte DG; Molesky AL; Komater VA; Buckley MJ; Diaz GJ; Gagne GD; Zhou D; Deng X; Pan L; Roberts EM; Diehl MS; Wetter JM; Marsh KC; Fox GB; Brioni JD; Esbenshade TA; Hancock AA
    Biochem Pharmacol; 2007 Apr; 73(8):1243-55. PubMed ID: 17371699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro optimization of structure activity relationships of analogues of A-331440 combining radioligand receptor binding assays and micronucleus assays of potential antiobesity histamine H3 receptor antagonists.
    Hancock AA; Diehl MS; Faghih R; Bush EN; Krueger KM; Krishna G; Miller TR; Wilcox DM; Nguyen P; Pratt JK; Cowart MD; Esbenshade TA; Jacobson PB
    Basic Clin Pharmacol Toxicol; 2004 Sep; 95(3):144-52. PubMed ID: 15447739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.
    Ligneau X; Lin J; Vanni-Mercier G; Jouvet M; Muir JL; Ganellin CR; Stark H; Elz S; Schunack W; Schwartz J
    J Pharmacol Exp Ther; 1998 Nov; 287(2):658-66. PubMed ID: 9808693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H3 receptor ligands.
    Tedford CE; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Handley MK; Yates SL
    J Pharmacol Exp Ther; 1999 May; 289(2):1160-8. PubMed ID: 10215700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
    Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.
    Cowart M; Faghih R; Curtis MP; Gfesser GA; Bennani YL; Black LA; Pan L; Marsh KC; Sullivan JP; Esbenshade TA; Fox GB; Hancock AA
    J Med Chem; 2005 Jan; 48(1):38-55. PubMed ID: 15634000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects.
    Esbenshade TA; Krueger KM; Miller TR; Kang CH; Denny LI; Witte DG; Yao BB; Fox GB; Faghih R; Bennani YL; Williams M; Hancock AA
    J Pharmacol Exp Ther; 2003 Jun; 305(3):887-96. PubMed ID: 12606603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
    Krause M; Ligneau X; Stark H; Garbarg M; Schwartz JC; Schunack W
    J Med Chem; 1998 Oct; 41(21):4171-6. PubMed ID: 9767653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists.
    Dvorak CA; Apodaca R; Barbier AJ; Berridge CW; Wilson SJ; Boggs JD; Xiao W; Lovenberg TW; Carruthers NI
    J Med Chem; 2005 Mar; 48(6):2229-38. PubMed ID: 15771465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new family of H3 receptor antagonists based on the natural product Conessine.
    Santora VJ; Covel JA; Hayashi R; Hofilena BJ; Ibarra JB; Pulley MD; Weinhouse MI; Sengupta D; Duffield JJ; Semple G; Webb RR; Sage C; Ren A; Pereira G; Knudsen J; Edwards JE; Suarez M; Frazer J; Thomsen W; Hauser E; Whelan K; Grottick AJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1490-4. PubMed ID: 18194865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substituted N-phenylcarbamates as histamine H3 receptor antagonists with improved in vivo potency.
    Reidemeister S; Stark H; Ligneau X; Ganellin CR; Schwartz JC; Schunack W
    Pharmazie; 2000 Feb; 55(2):83-6. PubMed ID: 10723763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-[6-(2-Aminoethyl)naphthalen-2-yl]benzonitriles are potent histamine H3 receptor antagonists with high CNS penetration.
    Black LA; Nersesian DL; Sharma P; Ku YY; Bennani YL; Marsh KC; Miller TR; Esbenshade TA; Hancock AA; Cowart M
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1443-6. PubMed ID: 17169555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency.
    Sun M; Zhao C; Gfesser GA; Thiffault C; Miller TR; Marsh K; Wetter J; Curtis M; Faghih R; Esbenshade TA; Hancock AA; Cowart M
    J Med Chem; 2005 Oct; 48(20):6482-90. PubMed ID: 16190774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.